Phaseline

Companies › Olatec Therapeutics

Olatec Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 4 registered trials: 3 Phase 2, 1 Phase 1; Neurology, Immunology, Metabolic and endocrine, Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Dapansutrile
NACHT, LRR and PYD domains-containing protein 3 inhibitor
NLRP3Phase 2Acute Gout Flare; Parkinson Disease; Diabetes Mellitus, Type 2; MelanomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT05658575DapansutrilePhase 2Acute Gout FlareImmunologyDec 2026
NCT04971499DapansutrilePhase 1MelanomaOncologyApr 2027
NCT07157735DapansutrilePhase 2Parkinson DiseaseNeurologyMay 2027
NCT06047262DapansutrilePhase 2Diabetes Mellitus, Type 2Metabolic and endocrineJul 2028

Targets

NLRP3 (1)

Companies with the same targets

Highlightll Pharmaceutical (USA) AC Immune

Companies built like this

Shenzhen Wingor Biotechnology NeuroBiogen Corxel Pharmaceuticals Shanghai Jiaolian Drug Research and Development Urovant Sciences

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.